Omnicell, Inc. (OMCL) Shares Bought by Azimuth Capital Management LLC
Azimuth Capital Management LLC grew its stake in Omnicell, Inc. (NASDAQ:OMCL) by 4.2% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 123,050 shares of the company’s stock after purchasing an additional 4,975 shares during the period. Azimuth Capital Management LLC’s holdings in Omnicell were worth $9,947,000 at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. Sturgeon Ventures LLP purchased a new position in Omnicell during the 1st quarter worth $2,368,000. Swiss National Bank grew its stake in Omnicell by 4.0% during the 1st quarter. Swiss National Bank now owns 72,200 shares of the company’s stock worth $5,837,000 after buying an additional 2,800 shares during the last quarter. Envestnet Asset Management Inc. grew its stake in Omnicell by 5.7% during the 1st quarter. Envestnet Asset Management Inc. now owns 56,482 shares of the company’s stock worth $4,566,000 after buying an additional 3,026 shares during the last quarter. Wells Fargo & Company MN grew its stake in Omnicell by 3.7% during the 1st quarter. Wells Fargo & Company MN now owns 191,582 shares of the company’s stock worth $15,487,000 after buying an additional 6,819 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its stake in Omnicell by 709.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 231,236 shares of the company’s stock worth $18,694,000 after buying an additional 202,682 shares during the last quarter. 97.32% of the stock is owned by institutional investors and hedge funds.
In other Omnicell news, EVP Dan S. Johnston sold 8,210 shares of Omnicell stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $81.16, for a total transaction of $666,323.60. Following the completion of the sale, the executive vice president now owns 36,504 shares of the company’s stock, valued at approximately $2,962,664.64. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Peter J. Kuipers sold 24,504 shares of Omnicell stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $83.97, for a total value of $2,057,600.88. Following the sale, the insider now directly owns 64,618 shares of the company’s stock, valued at approximately $5,425,973.46. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 176,568 shares of company stock valued at $13,233,495. 2.77% of the stock is currently owned by insiders.
Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, April 25th. The company reported $0.61 EPS for the quarter, topping the Zacks’ consensus estimate of $0.23 by $0.38. Omnicell had a return on equity of 11.10% and a net margin of 4.74%. The company had revenue of $202.50 million during the quarter, compared to analysts’ expectations of $199.72 million. During the same quarter in the previous year, the firm posted $0.29 EPS. The firm’s revenue was up 10.9% compared to the same quarter last year. On average, equities research analysts forecast that Omnicell, Inc. will post 2.06 earnings per share for the current fiscal year.
OMCL has been the topic of several research analyst reports. Zacks Investment Research downgraded Omnicell from a “hold” rating to a “sell” rating in a research note on Monday, March 25th. Craig Hallum downgraded Omnicell from a “buy” rating to a “hold” rating and set a $84.00 target price on the stock. in a research note on Friday, April 26th. TheStreet downgraded Omnicell from a “b” rating to a “c+” rating in a research note on Thursday, April 25th. Piper Jaffray Companies restated a “neutral” rating and set a $70.00 target price on shares of Omnicell in a research note on Friday, February 8th. They noted that the move was a valuation call. Finally, Dougherty & Co boosted their target price on Omnicell from $78.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, March 7th. Five investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $79.89.
Omnicell Company Profile
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
See Also: Beige Book
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.